100 related articles for article (PubMed ID: 17541498)
1. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
[TBL] [Abstract][Full Text] [Related]
2. [Bone mineral density in women with rheumatoid arthritis: A link between immune and biochemical markers].
Dobrovolskaya OV; Demin NV; Kozyreva MV; Samarkina EY; Diatroptov ME; Toroptsova NV
Ter Arkh; 2024 Jun; 96(5):494-499. PubMed ID: 38829811
[TBL] [Abstract][Full Text] [Related]
3. Non-association between polymorphisms of the frizzled receptor genes and bone mineral density in postmenopausal Korean women.
Kim JG; Kim H; Jee BC; Suh CS; Choi YM; Moon SY
J Korean Med Sci; 2009 Jun; 24(3):443-7. PubMed ID: 19543507
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
Kulik-Rechberger B; Kozłowska M
J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
[TBL] [Abstract][Full Text] [Related]
5. The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis.
Masi L; Maddali Bongi S; Angotti C; Del Monte F; Carbonell Sala S; Basetti M; Amedei A; Falchetti A; Brandi ML
Clin Cases Miner Bone Metab; 2007 May; 4(2):156-60. PubMed ID: 22461216
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report.
Zavala-Cerna MG; Moran-Moguel MC; Cornejo-Toledo JA; Gonzalez-Montoya NG; Sanchez-Corona J; Salazar-Paramo M; Nava-Zavala AH; Aguilar-Chavez EA; Alcaraz-Lopez MF; Gonzalez-Sanchez AG; Gonzalez-Lopez L; Gamez-Nava JI
J Immunol Res; 2015; 2015():376197. PubMed ID: 26065000
[TBL] [Abstract][Full Text] [Related]
7. Effect of Disease-related Variables on Bone Mineral Density in Patients with Rheumatoid Arthritis.
Naik S; Sonawale A; Sonawale K; Goyal A
J Assoc Physicians India; 2024 Jan; 72(1):47-50. PubMed ID: 38736074
[TBL] [Abstract][Full Text] [Related]
8. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
LaCroix AZ; Jackson RD; Aragaki A; Kooperberg C; Cauley JA; Chen Z; Leboff MS; Duggan D; Wactawski-Wende J
Bone; 2013 Oct; 56(2):474-81. PubMed ID: 23735608
[TBL] [Abstract][Full Text] [Related]
9. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
Sarink D; Schock H; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Arveux P; Fournier A; Kvaskoff M; Boeing H; Karakatsani A; Trichopoulou A; La Vecchia C; Masala G; Agnoli C; Panico S; Tumino R; Sacerdote C; van Gils CH; Peeters PHM; Weiderpass E; Agudo A; Rodríguez-Barranco M; Huerta JM; Ardanaz E; Gil L; Kaw KT; Schmidt JA; Dossus L; His M; Aune D; Riboli E; Kaaks R; Fortner RT
BMC Cancer; 2018 Oct; 18(1):1010. PubMed ID: 30348163
[TBL] [Abstract][Full Text] [Related]
11. Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.
Sarink D; Yang J; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Fournier A; Mancini FR; Kvaskoff M; Boeing H; Trichopoulou A; Karakatsani A; Valanou E; Agnoli C; Sacerdote C; Masala G; Mattiello A; Tumino R; Van Gils CH; Skeie G; Gram IT; Weiderpass E; Lujan-Barroso L; Petrova D; Santiuste C; Quirós JR; Barricarte A; Amiano P; Travis RC; Gunter M; Dossus L; Christakoudi S; Kaaks R; Fortner RT
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1746-1754. PubMed ID: 31292137
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density loss in postmenopausal onset rheumatoid arthritis is not greater than premenopausal onset disease.
Heidari B; Heidari P
Caspian J Intern Med; 2014; 5(4):213-8. PubMed ID: 25489432
[TBL] [Abstract][Full Text] [Related]
13. Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.
Sapunarova K; Goranova-Marinova V; Georgiev P; Deneva T; Tsvetkova S; Grudeva-Popova Z
Ann Med; 2020; 52(3-4):94-108. PubMed ID: 32212941
[No Abstract] [Full Text] [Related]
14. Correlation of serum matrix metalloproteinase 3 with osteoporosis in patients of postmenopausal rheumatoid arthritis.
Ji R; Yang L; Shi G; Sun J; Cao P
Hum Immunol; 2024 May; 85(3):110807. PubMed ID: 38701721
[TBL] [Abstract][Full Text] [Related]
15. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density.
Cawley NX; Yanik T; Woronowicz A; Chang W; Marini JC; Loh YP
Am J Physiol Endocrinol Metab; 2010 Aug; 299(2):E189-97. PubMed ID: 20460579
[TBL] [Abstract][Full Text] [Related]
16. Effects of walnut consumption for 2 years on older adults' bone health in the Walnuts and Healthy Aging (WAHA) trial.
Oliver-Pons C; Sala-Vila A; Cofán M; Serra-Mir M; Roth I; Valls-Pedret C; Domènech M; Ortega E; Rajaram S; Sabaté J; Ros E; Chiva-Blanch G
J Am Geriatr Soc; 2024 May; ():. PubMed ID: 38818857
[TBL] [Abstract][Full Text] [Related]
17. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease.
Wiebe E; Huscher D; Schaumburg D; Palmowski A; Hermann S; Buttgereit T; Biesen R; Burmester GR; Palmowski Y; Boers M; Stone JH; Dejaco C; Buttgereit F
Ann Rheum Dis; 2022 Aug; 81(9):1313-1322. PubMed ID: 35680387
[TBL] [Abstract][Full Text] [Related]
18. Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis.
Efendioğlu M; Şanli E; Türkoğlu C; Balak N
Noro Psikiyatr Ars; 2021 Jun; 58(2):133-136. PubMed ID: 34188596
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.
Pietschmann P; Butylina M; Kerschan-Schindl K; Sipos W
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955873
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
